The stock of Bristol-Myers Squibb Co (NYSE:BMY) last traded at $46.89, up 0.09% from the previous session.
BMY stock price is now -9.86% away from the 50-day moving average and -13.42% away from the 200-day moving average. The market capitalization of the company currently stands at $95.42B.
On April 22, 2025, Cantor Fitzgerald recently initiated its ‘Neutral’ rating on the stock quoting a target price of $55, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Hickey Benjamin, President, RayzeBio Org. sold 97 shares of the company’s stock on May 09 ’25. The stock was sold for $3,702 at an average price of $38.01. Upon completion of the transaction, the President, RayzeBio Org. now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 25 ’25, EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought 4,250 shares of the business’s stock. A total of $202,215 was incurred on buying the stock at an average price of $47.58. This leaves the insider owning 83,513 shares of the company worth $3.92 million. A total of 0.10% of the company’s stock is owned by insiders.
During the past 12 months, Bristol-Myers Squibb Co has had a low of $39.35 and a high of $63.33. As of last week, the company has a debt-to-equity ratio of 2.95, a current ratio of 1.28, and a quick ratio of 1.17.
The net profit margin was 11.38% and return on equity was 31.99% for BMY. The company reported revenue of $11.2 billion for the quarter, compared to $11.87 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.6 percent.
